According to IHC evaluation of HR, Ki67 expression levels and HER2 status, a “surrogate” classification of estrogen receptor (ER) positive (+)/HER2 negative BC in luminal A- and luminal B-like tumors has been established and widely used in clinical practice (4). This evidence concerns the gene ERBB2 and breast cancer.